Cost-Effectivenes of Autologous Stem Cell Transplantation (ASCT) in Over 65 Years New Diagnosed Multiple Myeloma (NDMM) Patients

Eligibility of candidates of ASCT in NDMM patients is defined in most health institutions by the age at diagnosis (generally under 65y) and not by biological or functional age. In the last 2 decades we have seen a substantial improvements in the prognosis of these patients, especially in young people, based on the better induction schemes, more effective and less toxic, and an intensification treatment that improve the depth and duration of response with high dose chemotherapy supported by ASCT.